Literature DB >> 25663579

Measurement of chemotherapy-induced alopecia-time to change.

C J G van den Hurk1, J Winstanley, A Young, F Boyle.   

Abstract

Data on chemotherapy-induced alopecia (CIA) as a side effect of cancer treatment are scarce. CIA is given minimal attention in clinical trials and in the literature. However, when asking the patients with cancer for their opinion, CIA appears to have a major impact, particularly on body image and quality of life. Currently, there is no commonly used measure to evaluate CIA; It is time to improve the management and measurement of CIA.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25663579     DOI： 10.1007/s00520-015-2647-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  13 in total

1.  Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia.

Authors:  C J G van den Hurk; W P M Breed; J W R Nortier
Journal:  Support Care Cancer       Date:  2012-04-27       Impact factor: 3.603

2.  Have men been overlooked? A comparison of young men and women's experiences of chemotherapy-induced alopecia.

Authors:  Shona Hilton; Kate Hunt; Carol Emslie; Maria Salinas; Sue Ziebland
Journal:  Psychooncology       Date:  2008-06       Impact factor: 3.894

3.  Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.

Authors:  L Del Mastro; M Venturini; R Lionetto; F Carnino; D Guarneri; L Gallo; A Contu; P Pronzato; L Vesentini; M Bergaglio; S Comis; R Rosso
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

4.  Enhancing therapeutic decision making when options abound: toxicities matter.

Authors:  Nicole M Kuderer; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2014-05-27       Impact factor: 44.544

5.  Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia.

Authors:  Corina J van den Hurk; M Elske van den Akker-van Marle; Wim P Breed; Lonneke V van de Poll-Franse; Johan W Nortier; Jan W Coebergh
Journal:  Acta Oncol       Date:  2013-09-23       Impact factor: 4.089

6.  Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial.

Authors:  Christoph Zielinski; Semir Beslija; Zrinka Mrsic-Krmpotic; Marzena Welnicka-Jaskiewicz; Christoph Wiltschke; Zsuzsanna Kahan; Mislav Grgic; Valentina Tzekova; Moshe Inbar; Jozika Cervek; Ivan Chernozemsky; Janos Szanto; Stanislav Spanik; Maria Wagnerova; Nicolae Ghilezan; Janusz Pawlega; Damir Vrbanec; Dmitry Khamtsov; Victoria Soldatenkova; Thomas Brodowicz
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

7.  Cancer and stigma: experience of patients with chemotherapy-induced alopecia.

Authors:  Sophia Rosman
Journal:  Patient Educ Couns       Date:  2004-03

8.  The impact of cancer and chemotherapy: perceptual similarities and differences between cancer patients, nurses and physicians.

Authors:  Marco Mulders; Ad Vingerhoets; Wim Breed
Journal:  Eur J Oncol Nurs       Date:  2008-01-31       Impact factor: 2.398

9.  Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.

Authors:  N Kluger; W Jacot; E Frouin; V Rigau; S Poujol; O Dereure; B Guillot; G Romieu; D Bessis
Journal:  Ann Oncol       Date:  2012-05-09       Impact factor: 32.976

10.  Familiarity, opinions, experiences and knowledge about scalp cooling: a Dutch survey among breast cancer patients and oncological professionals.

Authors:  Mijke Peerbooms; Corina Jg van den Hurk; Wim Pm Breed
Journal:  Asia Pac J Oncol Nurs       Date:  2015 Jan-Mar
View more
  5 in total

1.  Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer.

Authors:  Hope S Rugo; Paula Klein; Susan Anitra Melin; Sara A Hurvitz; Michelle E Melisko; Anne Moore; Glen Park; Jules Mitchel; Erika Bågeman; Ralph B D'Agostino; Elizabeth S Ver Hoeve; Laura Esserman; Tessa Cigler
Journal:  JAMA       Date:  2017-02-14       Impact factor: 56.272

Review 2.  Hair disorders in cancer survivors.

Authors:  Azael Freites-Martinez; Jerry Shapiro; Corina van den Hurk; Shari Goldfarb; Joaquin J Jimenez; Anthony M Rossi; Ralf Paus; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2018-04-14       Impact factor: 11.527

3.  Barriers and enablers to implementing scalp cooling in Australia: a qualitative study of health professionals' attitudes to and experience with scalp cooling.

Authors:  Joanne M Shaw; Jane O'Brien; Susan Chua; Richard De Boer; Rachel Dear; Nicholas Murray; Fran Boyle
Journal:  Support Care Cancer       Date:  2017-08-29       Impact factor: 3.603

4.  Results of 20- versus 45-min post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia.

Authors:  Manon M C Komen; Wim P M Breed; Carolien H Smorenburg; Tjeerd van der Ploeg; S H Goey; Jacobus J M van der Hoeven; Johan W R Nortier; Corina J G van den Hurk
Journal:  Support Care Cancer       Date:  2016-01-25       Impact factor: 3.603

5.  Improving Information Provision on Chemotherapy-Induced Alopecia and Scalp Cooling: A Comprehensive Approach Including A Website and Web-Based Decision Tool.

Authors:  Corina van den Hurk; Paulien Keizer-Heldens; Ilse Raats; Kim Hoeijmakers; Floortje Mols
Journal:  Asia Pac J Oncol Nurs       Date:  2019 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.